Literature DB >> 3581698

Serum gold concentrations during treatment with auranofin.

P L Van Riel, F W Gribnau, L B Van de Putte, C W Arts, A Van Aernsbergen.   

Abstract

Serum gold concentrations were measured in rheumatoid arthritis patients during chronic treatment with the orally adsorbable gold compound auranofin. In agreement with data in the literature, the highest serum gold concentration was reached after 16 weeks of treatment with 6 mg auranofin daily. A striking finding in this study was that thereafter the serum gold concentrations did not appear to plateau but declined gradually. Statistically this resulted in a significantly lower concentration after one year as compared with week 16 (p less than 0.05, paired t-test). It is suggested that a shift from protein bound gold to cell-bound gold might be the explanation.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3581698     DOI: 10.1007/bf02201000

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  17 in total

1.  DIAGNOSTIC criteria for rheumatoid arthritis: 1958 revision by a committee of the American Rheumatism Association.

Authors: 
Journal:  Ann Rheum Dis       Date:  1959-03       Impact factor: 19.103

2.  Gold Therapy in Rheumatoid Arthritis: Final Report of a Multicentre Controlled Trial.

Authors: 
Journal:  Ann Rheum Dis       Date:  1961-12       Impact factor: 19.103

Review 3.  Monitoring gold plasma levels in rheumatoid arthritis.

Authors:  A Lorber
Journal:  Clin Pharmacokinet       Date:  1977 Mar-Apr       Impact factor: 6.447

4.  Serum gold determinations in patients with rheumatoid arthritis receiving sodium aurothiomalate.

Authors:  J D Jessop; R G Johns
Journal:  Ann Rheum Dis       Date:  1973-05       Impact factor: 19.103

5.  Cell-bound gold (CBG) in patients treated with aurothioglucose and with auranofin. A comparison of different methods of determination.

Authors:  P L van Riel; F W Gribnau; L B van de Putte
Journal:  J Rheumatol       Date:  1983-08       Impact factor: 4.666

6.  Distribution of gold in serum erythrocytes and white blood cells after in vitro incubation and during chrysotherapy with different gold compounds.

Authors:  J D Herrlinger; C Alsen; R Beress; U Hecker; W Weikert
Journal:  J Rheumatol Suppl       Date:  1982 Jul-Aug

7.  Association of HLA antigens, toxic reactions and therapeutic response to auranofin and aurothioglucose in patients with rheumatoid arthritis.

Authors:  P L van Riel; P Reekers; L B van de Putte; F W Gribnau
Journal:  Tissue Antigens       Date:  1983-09

8.  Comparison of auranofin, gold sodium thiomalate, and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial.

Authors:  J R Ward; H J Williams; M J Egger; J C Reading; E Boyce; M Altz-Smith; C O Samuelson; R F Willkens; M A Solsky; S P Hayes
Journal:  Arthritis Rheum       Date:  1983-11

9.  Single dose pharmacokinetics of auranofin in rheumatoid arthritis.

Authors:  K Blocka; D E Furst; E Landaw; S Dromgoole; A Blomberg; H E Paulus
Journal:  J Rheumatol Suppl       Date:  1982 Jul-Aug

10.  Loose stools during auranofin treatment: clinical study and some pathogenetic possibilities.

Authors:  P L van Riel; F W Gribnau; L B van de Putte; S H Yap
Journal:  J Rheumatol       Date:  1983-04       Impact factor: 4.666

View more
  3 in total

1.  Gold nanoparticles: a revival in precious metal administration to patients.

Authors:  A S Thakor; J Jokerst; C Zavaleta; T F Massoud; S S Gambhir
Journal:  Nano Lett       Date:  2011-09-07       Impact factor: 11.189

2.  Combined inhibition of glycolysis, the pentose cycle, and thioredoxin metabolism selectively increases cytotoxicity and oxidative stress in human breast and prostate cancer.

Authors:  Ling Li; Melissa A Fath; Peter M Scarbrough; Walter H Watson; Douglas R Spitz
Journal:  Redox Biol       Date:  2014-12-10       Impact factor: 11.799

3.  Auranofin radiosensitizes tumor cells through targeting thioredoxin reductase and resulting overproduction of reactive oxygen species.

Authors:  Hui Wang; Soumaya Bouzakoura; Sven de Mey; Heng Jiang; Kalun Law; Inès Dufait; Cyril Corbet; Valeri Verovski; Thierry Gevaert; Olivier Feron; Dirk Van den Berge; Guy Storme; Mark De Ridder
Journal:  Oncotarget       Date:  2017-05-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.